Mirati Therapeutics oral drug MRTX849 shrinks tumours in early-stage trial Medical Dialogues Bureau2 Nov 2019 9:00 AM ISTOut of 17 patients enrolled in the Phase 1 trial of Mirati Therapeutics' oral drug MRTX849, 12 have been evaluated, including six with lung cancer and...
GSK ovarian cancer drug Zejula gets USFDA nod for wider use Medical Dialogues Bureau24 Oct 2019 10:00 AM ISTZejula was the lead compound of U.S. cancer specialist Tesaro, which GSK acquired for $5.1 billion last year. Zejula brought in sales of 57 million...
GSK collaborates with Lyell Immunopharma on cancer cell therapies Medical Dialogues Bureau12 Oct 2019 9:15 AM ISTCombining GSK plc's strong cell and gene therapy programmes with Lyell's technologies may allow the joint research team to maximize the activity and...
Merck wins USFDA nod for blockbuster drug Keytruda to treat head, neck cancer Medical Dialogues Bureau12 Jun 2019 9:50 AM ISTThe approval is based on results from a late-stage trial, where Keytruda showed a significant improvement in overall survival in cancer patients,...
Roche, GE Healthcare launch NAVIFY Tumor Board to enable personalised treatment decisions in cancer care Medical Dialogues Bureau3 Jun 2019 9:45 AM ISTThe new version of NAVIFY Tumor Board is initially available in the United States and Canada with additional markets to follow in the near future.New...
Novartis wins USFDA approval for first PI3K inhibitor for breast cancer Farhat Nasim27 May 2019 6:10 PM ISTThe drug, alpelisib, to be marketed under the brand name Piqray, belongs to a class of drugs known as PI3K inhibitors and is the first of its kind to...
